在B细胞淋巴瘤中,多 (ADP-Ribose) 聚合酶1和2:致病作用和治疗影响
Andrea Molina-Alvarez1, Blanca Sanchez-Gonzalez2, Luis Colomo1
1Department of Pathology, Hospital del Mar, Barcelona, Spain; Hospital del Mar Research Institute, Barcelona, Spain; Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
The American journal of pathology
|July 27, 2025
概括
向多 (ADP-ribose) 聚合酶-2 (PARP-2) 为B细胞淋巴瘤提供了一种新的策略,因为PARP-1和PARP-2在瘤发育中具有相反的作用. 选择性PARP-2抑制显示出对攻击性或复发性淋巴瘤的前景.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- B细胞淋巴瘤是由DNA损伤反应 (DDR) 缺陷驱动的复杂癌症.
- 多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 针对淋巴瘤中的DDR漏洞.
- 在B细胞淋巴瘤的发展中,PARP-1和PARP-2具有不同的,对立的作用.
研究的目的:
- 评估PARP-1和PARP-2在B细胞淋巴发育中的不同作用.
- 挑战目前泛PARP抑制的模式.
- 突出了对异形选择性PARP抑制剂策略的需要.
主要方法:
- 研究DDR缺陷B细胞淋巴瘤的临床前研究.
- 对PARP抑制剂早期临床试验的分析.
- 对PARP-1和PARP-2功能的新兴证据的审查.
主要成果:
- 失去PARP-1会加速淋巴发育,而失去PARP-2会延迟瘤的进展.
- 非选择性PARP抑制剂在临床试验中显示出令人鼓舞的结果.
- 选择性PARP-1抑制剂正在临床试验中,但选择性PARP-2抑制剂仍处于早期开发阶段.
结论:
- 由于PARP-1和PARP-2的不同作用,需要选择性治疗策略.
- 选择性向PARP-2是一种有前途的方法,用于攻击性,耐火性或复发性B细胞淋巴瘤.
- 未来的研究应该集中在PARP-2抑制剂,生物标志物和用于血液恶性瘤精密瘤的组合疗法上.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Intrinsic Apoptotic Pathway
6.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
Translesion DNA Polymerases
10.2K
Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
10.2K
Long-patch Base Excision Repair
7.2K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.2K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
B Cell Activation and Differentiation
5.9K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
5.9K


